AI Summary Therapeutic phlebotomy is the first-line treatment for hereditary hemochromatosis, with iron chelators used when phlebotomy is not appropriate.
Medically reviewed.
Hereditary hemochromatosis therapy is a group of treatments used to manage hereditary hemochromatosis, a genetic disorder that causes the body to absorb too much iron. Without treatment, that excess iron builds up in the liver, heart, and other organs over time. This group includes therapeutic phlebotomy, the first-line treatment, and iron chelation medications — deferasirox (Exjade, Jadenu), deferoxamine (Desferal), and deferiprone (Ferriprox) — used when phlebotomy is not appropriate.
This page explains how these therapies work, who may benefit from each, and what to expect during treatment. You can also connect with a liver specialist to discuss whether one of these approaches fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
HEREDITARY HEMOCHROMATOSIS THERAPY OVERVIEW
Hereditary hemochromatosis therapy centers on lowering total body iron before it damages the liver, heart, and other organs. Therapeutic phlebotomy — regularly removing blood, similar to a blood donation — is the first-line, standard treatment. Iron chelation medications are considered when phlebotomy is not appropriate or not tolerated. Care is typically guided by regular iron-level testing, and treatment plans are personalized based on ferritin and transferrin saturation levels, organ involvement, and overall health.
You can explore the individual hereditary hemochromatosis therapies below and learn how they may support iron reduction and organ protection. Because the right approach depends on your specific iron levels and health history, connecting with a liver specialist can help you understand which option fits your care plan and ensure ongoing monitoring as treatment progresses.
Therapeutic phlebotomy removes iron-containing red blood cells from circulation, forcing the body to mobilize stored iron for new red blood cell production. It is the standard, first-line treatment for confirmed hereditary hemochromatosis with iron overload.
Explore this therapy:
Deferasirox (Exjade, Jadenu), Deferoxamine (Desferal), and Deferiprone (Ferriprox) bind excess iron in the body and promote its elimination. They are considered for chronic iron overload when phlebotomy is not appropriate or not effective.
Explore chelation therapies:
Most people with confirmed hereditary hemochromatosis and iron overload may benefit from treatment. Therapeutic phlebotomy is the first-line option because it lowers total body iron and helps prevent iron damage to the liver, heart, and pancreas. It works best when it starts before cirrhosis or diabetes develops.
Iron chelation is not the usual first choice. Your healthcare provider may consider it if phlebotomy cannot manage your iron overload or you are not a candidate for blood removal. Deferoxamine may be an option if you cannot tolerate oral chelators. Deferiprone may be used if other chelators do not work well enough or you cannot tolerate them.
DIET & LIFESTYLE SUPPORT
Hereditary hemochromatosis therapy works best alongside lifestyle changes. Diet, alcohol moderation, and ongoing monitoring all support the iron-reduction goals of phlebotomy and chelation therapy.
Patients are generally advised to avoid iron supplements and to limit vitamin C supplementation unless specifically directed, since both can increase iron absorption or mobilize iron during treatment.
Limiting alcohol helps protect the liver from added stress, and avoiding raw shellfish reduces the risk of Vibrio infection, which is a particular concern for people with iron overload.
Maintaining adequate hydration supports safe phlebotomy sessions, and regular follow-up testing helps guide how often treatment is needed.
A nutrition bar designed for liver health can be a simple, consistent way to help meet daily energy and protein goals alongside phlebotomy or chelation therapy.
Explore Liver Health Nutrition Bars
TREATMENT APPROACHES AND EVIDENCE
Therapeutic phlebotomy is the standard, first-line treatment for hereditary hemochromatosis and is the mainstay of care. Iron chelation medications were originally developed for other iron-overload conditions, such as transfusion-dependent anemias, and are used for hereditary hemochromatosis in selected cases where phlebotomy is not appropriate or not tolerated.
Because both approaches work by lowering total body iron, providers choose between them based on how well a person tolerates blood removal, their overall health, and their ferritin and transferrin saturation trends over time.
Therapeutic phlebotomy removes iron-containing red blood cells from circulation and is guided by regular monitoring of serum ferritin, transferrin saturation, hemoglobin, and hematocrit. It reduces the risk of cirrhosis, cardiomyopathy, and endocrine complications when started before organ damage occurs.
Deferasirox is an oral iron chelator taken once daily. It binds free iron and forms complexes that are excreted mainly in the feces, reducing iron accumulation in the liver, heart, and endocrine organs.
Deferoxamine is a parenteral (infused) iron chelator used when oral therapies are not suitable or effective. Deferiprone is an oral chelator that promotes iron excretion mainly through urine and can be combined with other chelators in resistant cases.
Chelation therapy is generally reserved for people whose iron overload cannot be managed with phlebotomy, or who are not candidates for blood removal. It is not a routine substitute for phlebotomy. Your healthcare provider weighs your iron burden, tolerance, and health history when deciding which approach fits your plan.
TREATMENT MONITORING
Regular monitoring helps your healthcare provider evaluate how your iron levels are responding to treatment and identify changes over time. Follow-up care may include blood tests and, in selected cases, imaging to track liver health and guide ongoing treatment frequency.
Ferritin and transferrin saturation are checked regularly to track total body iron and guide how often phlebotomy or chelation is needed.
Liver function tests track enzymes and other markers that show how your liver is responding to treatment and help flag any changes early.
Hemoglobin and hematocrit are checked before phlebotomy sessions to ensure safe treatment and avoid overtreatment or anemia.
Imaging and, in selected cases, biopsy can assess iron deposition and liver damage directly and help guide long-term treatment decisions.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
Hereditary hemochromatosis therapy centers on lowering total body iron before it damages organs. Therapeutic phlebotomy — regularly removing blood, similar to a blood donation — is the first-line, standard treatment. Iron chelation medications, including deferasirox (Exjade, Jadenu), deferoxamine (Desferal), and deferiprone (Ferriprox), are used when phlebotomy is not appropriate or not tolerated. Talk with your healthcare provider about which approach fits your treatment plan.
Therapeutic phlebotomy removes iron-containing red blood cells from circulation. As the body replaces these cells, it draws on stored iron reserves, gradually lowering the excess iron built up in the liver, heart, and pancreas. Iron chelation medications work differently: they bind free iron in the bloodstream and tissues and form complexes the body excretes through feces or urine, depending on the medication. Your healthcare provider can explain how each approach applies to your specific iron levels.
Most people with confirmed hereditary hemochromatosis and iron overload may benefit from therapeutic phlebotomy. Providers typically recommend it if you have elevated serum ferritin and/or transferrin saturation, or signs of iron buildup in the liver or other organs. Iron chelation may be considered if phlebotomy cannot manage your iron overload, if you are not a candidate for blood removal, or if you cannot tolerate other iron removal therapies. Your iron levels, overall health, and treatment history guide the choice.
Therapeutic phlebotomy has an induction phase — usually once weekly or every one to two weeks until target ferritin levels are reached — followed by a maintenance phase every two to four months, adjusted based on iron studies. It is a long-term, often lifelong management strategy. Iron chelators such as deferasirox and deferiprone are also long-term therapies, with duration guided by ongoing ferritin trends and organ iron levels.
Common risks of therapeutic phlebotomy include fatigue or lightheadedness after the procedure, low blood pressure, mild anemia if overtreated, and bruising at the needle site. Iron chelators can cause nausea, abdominal pain, diarrhea, skin rash, and changes in kidney or liver function; deferiprone carries a risk of neutropenia that requires frequent blood count monitoring. Your healthcare provider will monitor you regularly and can help manage any side effects that arise.
No, treatment works alongside lifestyle changes rather than replacing them. Patients are generally advised to avoid iron and vitamin C supplements unless directed, limit alcohol intake, avoid raw shellfish because of infection risk, and maintain adequate hydration. These habits support the iron-reduction goals of phlebotomy and chelation therapy and remain part of long-term care.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
